Coherus, CRI Combo Trial For Ovarian Cancer Treatment
08 May 2024 //
GLOBENEWSWIRE
ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study
07 Nov 2023 //
BUSINESSWIRE
ENB Presents Results from Ph 1b ENBOLDEN-101 Study in Solid Tumors Refractory
18 Jul 2023 //
BUSINESSWIRE
ENB Therapeutics to present at the 2023 Immuno-Oncology 360o Conferences
24 Jan 2023 //
BUSINESSWIRE